Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

•Universally agreed criteria for cisplatin ineligibility in LA SCCHN are needed.•Cisplatin-ineligible patients have limited adjuvant setting treatment options.•Radiotherapy alone is an evidence-based option for cisplatin-ineligible patients.•Randomized phase 3 trials of cisplatin-sparing regimens are urgently needed.